CLINICAL TRIALS PROFILE FOR TASIGNA

All Clinical Trials for tasigna

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00036738 ↗	Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, D	Completed	National Cancer Institute (NCI)	Phase 2	2001-07-13	This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia that has responded to previous treatment with imatinib mesylate, dasatinib, or nilotinib. Giving low doses of chemotherapy, such as fludarabine phosphate, and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving mycophenolate mofetil and cyclosporine after the transplant may stop this from happening.
NCT00036738 ↗	Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, D	Completed	Fred Hutchinson Cancer Research Center	Phase 2	2001-07-13	This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia that has responded to previous treatment with imatinib mesylate, dasatinib, or nilotinib. Giving low doses of chemotherapy, such as fludarabine phosphate, and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving mycophenolate mofetil and cyclosporine after the transplant may stop this from happening.
NCT00644878 ↗	Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib	Terminated	Novartis Pharmaceuticals	Phase 2	2008-10-01	This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib
NCT00702403 ↗	Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2008-08-14	This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Clinical Trial Conditions for tasigna

Condition Name

Condition Name for tasigna
Intervention	Trials
Chronic Myeloid Leukemia	10
Leukemia	4
Recurrent Adult Acute Lymphoblastic Leukemia	3
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia	3

Condition MeSH

Condition MeSH for tasigna
Intervention	Trials
Leukemia	33
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	32
Leukemia, Myeloid	31
Leukemia, Myeloid, Chronic-Phase	10

Clinical Trial Locations for tasigna

Trials by Country

Trials by Country for tasigna
Location	Trials
United States	165
Brazil	20
Spain	10
Italy	9
Canada	9

Trials by US State

Trials by US State for tasigna
Location	Trials
Texas	11
California	10
New York	9
North Carolina	7
Washington	7

Clinical Trial Progress for tasigna

Clinical Trial Phase

Clinical Trial Phase for tasigna
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	10
Phase 2	34

Clinical Trial Status

Clinical Trial Status for tasigna
Clinical Trial Phase	Trials
Completed	31
Terminated	13
Recruiting	11

Clinical Trial Sponsors for tasigna

Sponsor Name

Sponsor Name for tasigna
Sponsor	Trials
Novartis Pharmaceuticals	15
Novartis	11
National Cancer Institute (NCI)	10

Sponsor Type

Sponsor Type for tasigna
Sponsor	Trials
Other	83
Industry	47
NIH	11